Author

Sai Krishna Susarla

Observed name: Susarla, Sai Krishna

Institution: Indian Immunologicals (India)

Observed institution: Indian Immunologicals (India)

ORCID: 0000-0003-0435-6170

Observed ORCID: 0000-0003-0435-6170

OpenAlex ID: A5090821828

Immunogenicity and safety of a liquid Pentavalent (DTwP-Hb-Hib) combination vaccine manufactured by Human Biologicals Institute in 6–8 weeks old healthy infants: A phase III, randomized, single blind, non-inferiority study

2019 · Sai Krishna Susarla, Madhu Gupta, et al. · Vaccine · 8

Safety and immunogenicity of inactivated hepatitis-A vaccine developed by Human Biologicals Institute in two age groups of healthy subjects: A phase I open label study

2021 · Sai Krishna Susarla, Sonali Palkar, et al. · Vaccine · 6

Immunogenicity and safety of HavisureTM vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study

2023 · Sai Krishna Susarla, Madhu Gupta, et al. · Vaccine · 2

Longevity of humoral response in recipients of rabies pre-exposure prophylactic vaccination with Abhayrab®

2026 · Bhaskar Ganguly, Rajashakar Bellamcapu, et al. · Biologicals

A Phase II/III multicenter randomized single blind non-inferiority immunogenicity and safety study of TeddyVac™ vaccine of Human Biologicals Institute in healthy subjects of 10 years to 60 years of age

2024 · Sai Krishna Susarla, Manish Narang, et al. · Scandinavian Journal of Infectious Diseases

Immunogenicity and safety of Mebella™ vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority study

2023 · Sai Krishna Susarla, Rahul Jahagirdar, et al. · Vaccine

Works count: 7

Citation count: 16

H-index: 2

I10-index: